Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | ESR1 | P03372 | 17/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.52 |
| ▸ | ESRRG | P62508 | 12/20 | 0.52 |
| ▸ | ESRRB | O95718 | 4/20 | 0.52 |
| ▸ | ESRRA | P11474 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | PLD2 | O14939 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5004320 | 0.96 | ESR1 (0.52) | THRATHRBESR1ESR2ESRRG | |
| SCHEMBL5075821 | 0.93 | THRA (0.53) | THRATHRBESR1ESR2ESRRG | |
| SCHEMBL4637821 | 0.89 | ESR1 (0.50) | THRATHRBESR1ESR2ESRRG | |
| SCHEMBL5075269 | 0.89 | ESR1 (0.60) | THRATHRBESR1ESR2ESRRG | |
| SCHEMBL3818064 | 0.87 | ESR1 (0.56) | THRATHRBESR1ESR2ESRRG | |
| SCHEMBL3814114 | 0.84 | ESR1 (0.52) | THRATHRBESR1ESR2MEN1 | |
| SCHEMBL4637955 | 0.84 | ESR1 (0.60) | ESR1ESR2ESRRGESRRBESRRA | |
| SCHEMBL5052671 | 0.83 | ESR1 (0.51) | THRATHRBESR1ESR2ESRRG | |
| SCHEMBL5075012 | 0.83 | ESRRB (0.62) | THRATHRBESR1ESR2ESRRG | |
| SCHEMBL4893739 | 0.83 | ESR1 (0.56) | ESR1ESR2ESRRGESRRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255089-A1 | Menopausal or postmenopausal disorders, vasomotor symptoms, urogenital disorders, female sexual dysfunction, breast cancer, depression, diabetes, bone demineralization, and osteoporosis; substituted 2-(p-aminoalkoxyphenyl)-1,1-diphenylethylene derivatives | SMITHKLINE BEECHAM CORPORATION | 2008-10-16 | — | — | US | claimed |
| EP-1951250-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-08-06 | — | — | EP | claimed |
| WO-2007062151-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-31 | — | — | WO | claimed |
| US-20080255089-A1 | Menopausal or postmenopausal disorders, vasomotor symptoms, urogenital disorders, female sexual dysfunction, breast cancer, depression, diabetes, bone demineralization, and osteoporosis; substituted 2-(p-aminoalkoxyphenyl)-1,1-diphenylethylene derivatives | SMITHKLINE BEECHAM CORPORATION | 2008-10-16 | — | — | US | disclosed |
| US-20080255089-A1 | Menopausal or postmenopausal disorders, vasomotor symptoms, urogenital disorders, female sexual dysfunction, breast cancer, depression, diabetes, bone demineralization, and osteoporosis; substituted 2-(p-aminoalkoxyphenyl)-1,1-diphenylethylene derivatives | SMITHKLINE BEECHAM CORPORATION | 2008-10-16 | — | — | US | disclosed |
| US-20080255089-A1 | Menopausal or postmenopausal disorders, vasomotor symptoms, urogenital disorders, female sexual dysfunction, breast cancer, depression, diabetes, bone demineralization, and osteoporosis; substituted 2-(p-aminoalkoxyphenyl)-1,1-diphenylethylene derivatives | SMITHKLINE BEECHAM CORPORATION | 2008-10-16 | — | — | US | disclosed |
| EP-1951250-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007062151-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007062151-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255089-A1 | Menopausal or postmenopausal disorders, vasomotor symptoms, urogenital disorders, female sexual dysfunction, breast cancer, depression, diabetes, bone demineralization, and osteoporosis; substituted 2-(p-aminoalkoxyphenyl)-1,1-diphenylethylene derivatives | SHBG, ESR1, GPER1 | THRA 202/4885THRB 241/4885ESR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.